Novo Nordisk drops Him & Hers lawsuit

Core Perspective - Himson and Hers has transitioned its GOP1 business model to enhance access to affordable branded FDA-approved medications, discontinuing the advertisement of compounded GOPs [1] Business Model Shift - The company will now focus on providing FDA-approved medications and aims to attract new patients to its Viggovian Ompic platform, which aligns with its strategic goals [1] - Patients will have the opportunity to transition to these FDA-approved alternatives in consultation with their healthcare professionals, indicating a commitment to patient care [1] Legal Proceedings - The company has decided to drop current court proceedings related to the previous business model but retains the option to revisit them if necessary, suggesting a proactive approach to legal matters [1] - The focus is now on partnering with healthcare providers to expand access to affordable medications for patients [1]